Loading articles...

Quebec-based Medicago reports promising early Phase 1 test results of possible COVID-19 vaccine

Last Updated Nov 10, 2020 at 8:41 am EDT

File photo of a disposable plastic medical syringe with attached hypodermic needle. GI PHOTO STOCK.

QUEBEC — Medicago says it has received promising early test results for its plant-derived vaccine for COVID-19.

The Quebec City-based company says interim results of a Phase 1 clinical trial found that 100 per cent of subjects developed a promising antibody response after two doses of its COVID-19 vaccine candidate.

Medicago says the side effects were generally mild to moderate and short in duration.

RELATED: Pfizer says early data signals COVID-19 vaccine is effective

The Phase 1 clinical trial was a randomized, partially blinded study of 180 healthy people.

Based on the Phase 1 data, Medicago plans to proceed with a Phase 2/3 clinical trial for its COVID-19 vaccine candidate, subject to regulatory approval.

The federal government has signed a $173-million contract with Medicago to secure the rights to buy 76 million doses of its vaccine, should it meet health and safety standards.

This report by The Canadian Press was first published Nov. 10, 2020.

The Canadian Press

Latest Traffic & Weather
680 NEWS TRAFFIC @680NEWStraffic 680 News Traffic Twitter verified icon
Updated 30 minutes ago
COLLISION: WB 401 at Brock St. 3 left lanes and the ramp to Brock St. closed due to a crash #HWY401
Latest Traffic
680 NEWS WEATHER @680NEWSweather 
Updated Today at 06:55 PM
Retweeted @michellemackey: I’m calling it: put away your winter clothes, turn off the heat, and grab an ice cream. Spring warmth is here to stay i…
Latest Weather